{"entity":{"type":"insider","cik":"0001551139","url":"/insider/0001551139","json_url":"/insider/0001551139.json","name":"667, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":2117,"n_filings":185,"first":"2012-10-31","last":"2026-05-27","span_basis":"filed_date"},"name_variants":[{"name":"667, L.P.","source":"filing","n_filings":185,"first_seen":"2012-10-31","last_seen":"2026-05-27"}],"transactions":[{"id":6177542,"accession":"0001193125-26-242066","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-26-242066","line_url":"/filing/0001193125-26-242066","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"BeOne Medicines Ltd.","issuer_ticker":"ONC","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10998.0,"shares_display":"10,998","price_per_share":23.820778250591015,"price_display":"23.82","price_state":"stated","total_value":261980.9192,"total_display":"261,980.92","total_whole":"261,981","shares_owned_after":142570.0,"shares_owned_after_display":"142,570","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-22","filed_date":"2026-05-27","scope":"insider","n_lines":4},{"id":5026583,"accession":"0001193125-25-326820","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-326820","line_url":"/filing/0001193125-25-326820","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"Kodiak Sciences Inc.","issuer_ticker":"KOD","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2608696.0,"shares_display":"2,608,696","price_per_share":23.0,"price_display":"23.00","price_state":"stated","total_value":60000008.0,"total_display":"60,000,008.00","total_whole":"60,000,008","shares_owned_after":18358772.0,"shares_owned_after_display":"18,358,772","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-18","filed_date":"2025-12-19","scope":"insider","n_lines":2},{"id":4426555,"accession":"0001193125-25-315999","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-315999","line_url":"/filing/0001193125-25-315999","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2005813.0,"shares_display":"2,005,813","price_per_share":86.0,"price_display":"86.00","price_state":"stated","total_value":172499918.0,"total_display":"172,499,918.00","total_whole":"172,499,918","shares_owned_after":7955916.0,"shares_owned_after_display":"7,955,916","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-11","filed_date":"2025-12-11","scope":"insider","n_lines":2},{"id":4793249,"accession":"0000950170-25-110502","txn_seq":26,"anchor":"line-26","filing_url":"/filing/0000950170-25-110502","line_url":"/filing/0000950170-25-110502","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":59901.0,"shares_display":"59,901","price_per_share":385.1582856229445,"price_display":"385.16","price_state":"stated","total_value":23071366.4671,"total_display":"23,071,366.47","total_whole":"23,071,366","shares_owned_after":1931293.0,"shares_owned_after_display":"1,931,293","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-20","filed_date":"2025-08-20","scope":"insider","n_lines":22},{"id":4912913,"accession":"0000950170-25-110498","txn_seq":28,"anchor":"line-28","filing_url":"/filing/0000950170-25-110498","line_url":"/filing/0000950170-25-110498#line-28","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10128.0,"shares_display":"10,128","price_per_share":372.1573,"price_display":"372.16","price_state":"stated","total_value":3769209.1344,"total_display":"3,769,209.13","total_whole":"3,769,209","shares_owned_after":1859091.0,"shares_owned_after_display":"1,859,091","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-20","scope":"insider"},{"id":4912911,"accession":"0000950170-25-110498","txn_seq":27,"anchor":"line-27","filing_url":"/filing/0000950170-25-110498","line_url":"/filing/0000950170-25-110498#line-27","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8514.0,"shares_display":"8,514","price_per_share":359.3931,"price_display":"359.39","price_state":"stated","total_value":3059872.8534,"total_display":"3,059,872.85","total_whole":"3,059,873","shares_owned_after":1818414.0,"shares_owned_after_display":"1,818,414","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-20","scope":"insider"},{"id":4912907,"accession":"0000950170-25-110498","txn_seq":26,"anchor":"line-26","filing_url":"/filing/0000950170-25-110498","line_url":"/filing/0000950170-25-110498#line-26","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8328.0,"shares_display":"8,328","price_per_share":357.0232,"price_display":"357.02","price_state":"stated","total_value":2973289.2096,"total_display":"2,973,289.21","total_whole":"2,973,289","shares_owned_after":1807428.0,"shares_owned_after_display":"1,807,428","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-20","scope":"insider"},{"id":4912902,"accession":"0000950170-25-110498","txn_seq":25,"anchor":"line-25","filing_url":"/filing/0000950170-25-110498","line_url":"/filing/0000950170-25-110498#line-25","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5587.0,"shares_display":"5,587","price_per_share":362.3881,"price_display":"362.39","price_state":"stated","total_value":2024662.3147,"total_display":"2,024,662.31","total_whole":"2,024,662","shares_owned_after":1829444.0,"shares_owned_after_display":"1,829,444","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-20","scope":"insider"},{"id":4912896,"accession":"0000950170-25-110498","txn_seq":24,"anchor":"line-24","filing_url":"/filing/0000950170-25-110498","line_url":"/filing/0000950170-25-110498#line-24","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5494.0,"shares_display":"5,494","price_per_share":371.005,"price_display":"371.00","price_state":"stated","total_value":2038301.47,"total_display":"2,038,301.47","total_whole":"2,038,301","shares_owned_after":1848963.0,"shares_owned_after_display":"1,848,963","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-20","scope":"insider"},{"id":4912893,"accession":"0000950170-25-110498","txn_seq":23,"anchor":"line-23","filing_url":"/filing/0000950170-25-110498","line_url":"/filing/0000950170-25-110498#line-23","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5443.0,"shares_display":"5,443","price_per_share":361.3736,"price_display":"361.37","price_state":"stated","total_value":1966956.5048,"total_display":"1,966,956.50","total_whole":"1,966,957","shares_owned_after":1823857.0,"shares_owned_after_display":"1,823,857","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-20","scope":"insider"},{"id":4912887,"accession":"0000950170-25-110498","txn_seq":22,"anchor":"line-22","filing_url":"/filing/0000950170-25-110498","line_url":"/filing/0000950170-25-110498#line-22","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4798.0,"shares_display":"4,798","price_per_share":367.771,"price_display":"367.77","price_state":"stated","total_value":1764565.258,"total_display":"1,764,565.26","total_whole":"1,764,565","shares_owned_after":1839303.0,"shares_owned_after_display":"1,839,303","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-20","scope":"insider"},{"id":4912883,"accession":"0000950170-25-110498","txn_seq":21,"anchor":"line-21","filing_url":"/filing/0000950170-25-110498","line_url":"/filing/0000950170-25-110498#line-21","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2772.0,"shares_display":"2,772","price_per_share":363.7474,"price_display":"363.75","price_state":"stated","total_value":1008307.7928,"total_display":"1,008,307.79","total_whole":"1,008,308","shares_owned_after":1832216.0,"shares_owned_after_display":"1,832,216","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-20","scope":"insider"},{"id":4912878,"accession":"0000950170-25-110498","txn_seq":20,"anchor":"line-20","filing_url":"/filing/0000950170-25-110498","line_url":"/filing/0000950170-25-110498#line-20","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2747.0,"shares_display":"2,747","price_per_share":369.335,"price_display":"369.34","price_state":"stated","total_value":1014563.245,"total_display":"1,014,563.24","total_whole":"1,014,563","shares_owned_after":1843469.0,"shares_owned_after_display":"1,843,469","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-20","scope":"insider"},{"id":4912871,"accession":"0000950170-25-110498","txn_seq":19,"anchor":"line-19","filing_url":"/filing/0000950170-25-110498","line_url":"/filing/0000950170-25-110498#line-19","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2472.0,"shares_display":"2,472","price_per_share":358.21,"price_display":"358.21","price_state":"stated","total_value":885495.12,"total_display":"885,495.12","total_whole":"885,495","shares_owned_after":1809900.0,"shares_owned_after_display":"1,809,900","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-20","scope":"insider"},{"id":4912866,"accession":"0000950170-25-110498","txn_seq":18,"anchor":"line-18","filing_url":"/filing/0000950170-25-110498","line_url":"/filing/0000950170-25-110498#line-18","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2289.0,"shares_display":"2,289","price_per_share":366.2992,"price_display":"366.30","price_state":"stated","total_value":838458.8688,"total_display":"838,458.87","total_whole":"838,459","shares_owned_after":1834505.0,"shares_owned_after_display":"1,834,505","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-20","scope":"insider"},{"id":4912862,"accession":"0000950170-25-110498","txn_seq":17,"anchor":"line-17","filing_url":"/filing/0000950170-25-110498","line_url":"/filing/0000950170-25-110498#line-17","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1923.0,"shares_display":"1,923","price_per_share":353.8755,"price_display":"353.88","price_state":"stated","total_value":680502.5865,"total_display":"680,502.59","total_whole":"680,503","shares_owned_after":1798184.0,"shares_owned_after_display":"1,798,184","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-20","scope":"insider"},{"id":4912857,"accession":"0000950170-25-110498","txn_seq":16,"anchor":"line-16","filing_url":"/filing/0000950170-25-110498","line_url":"/filing/0000950170-25-110498#line-16","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1419.0,"shares_display":"1,419","price_per_share":368.84,"price_display":"368.84","price_state":"stated","total_value":523383.96,"total_display":"523,383.96","total_whole":"523,384","shares_owned_after":1840722.0,"shares_owned_after_display":"1,840,722","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-20","scope":"insider"},{"id":4912853,"accession":"0000950170-25-110498","txn_seq":15,"anchor":"line-15","filing_url":"/filing/0000950170-25-110498","line_url":"/filing/0000950170-25-110498#line-15","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":933.0,"shares_display":"933","price_per_share":372.1573,"price_display":"372.16","price_state":"stated","total_value":347222.7609,"total_display":"347,222.76","total_whole":"347,223","shares_owned_after":194625.0,"shares_owned_after_display":"194,625","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-20","scope":"insider"},{"id":4912849,"accession":"0000950170-25-110498","txn_seq":14,"anchor":"line-14","filing_url":"/filing/0000950170-25-110498","line_url":"/filing/0000950170-25-110498#line-14","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":916.0,"shares_display":"916","price_per_share":355.0,"price_display":"355.00","price_state":"stated","total_value":325180.0,"total_display":"325,180.00","total_whole":"325,180","shares_owned_after":1799100.0,"shares_owned_after_display":"1,799,100","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-20","scope":"insider"},{"id":4912843,"accession":"0000950170-25-110498","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0000950170-25-110498","line_url":"/filing/0000950170-25-110498#line-13","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":784.0,"shares_display":"784","price_per_share":359.3931,"price_display":"359.39","price_state":"stated","total_value":281764.1904,"total_display":"281,764.19","total_whole":"281,764","shares_owned_after":190877.0,"shares_owned_after_display":"190,877","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-20","scope":"insider"},{"id":4912839,"accession":"0000950170-25-110498","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0000950170-25-110498","line_url":"/filing/0000950170-25-110498#line-12","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":767.0,"shares_display":"767","price_per_share":357.0232,"price_display":"357.02","price_state":"stated","total_value":273836.7944,"total_display":"273,836.79","total_whole":"273,837","shares_owned_after":189865.0,"shares_owned_after_display":"189,865","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-20","scope":"insider"},{"id":4912834,"accession":"0000950170-25-110498","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0000950170-25-110498","line_url":"/filing/0000950170-25-110498#line-11","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":515.0,"shares_display":"515","price_per_share":362.3881,"price_display":"362.39","price_state":"stated","total_value":186629.8715,"total_display":"186,629.87","total_whole":"186,630","shares_owned_after":191894.0,"shares_owned_after_display":"191,894","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-20","scope":"insider"},{"id":4912831,"accession":"0000950170-25-110498","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0000950170-25-110498","line_url":"/filing/0000950170-25-110498#line-10","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":506.0,"shares_display":"506","price_per_share":371.005,"price_display":"371.00","price_state":"stated","total_value":187728.53,"total_display":"187,728.53","total_whole":"187,729","shares_owned_after":193692.0,"shares_owned_after_display":"193,692","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-20","scope":"insider"},{"id":4912826,"accession":"0000950170-25-110498","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0000950170-25-110498","line_url":"/filing/0000950170-25-110498#line-9","is_derivative":false,"issuer_cik":"0001087939","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001087939","owner_cik":null,"owner_name":"667, L.P.; BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP","owner_display_name":"667, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":502.0,"shares_display":"502","price_per_share":361.3736,"price_display":"361.37","price_state":"stated","total_value":181409.5472,"total_display":"181,409.55","total_whole":"181,410","shares_owned_after":191379.0,"shares_owned_after_display":"191,379","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-20","scope":"insider"}],"collapsed":true,"next_cursor":"2025-08-18|4912826","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001651308","name":"BeOne Medicines Ltd.","url":"/issuer/0001651308","role":"Director, Ten percent owner","n_filings":11,"first_seen":"2016-02-09","last_seen":"2026-05-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001468748","name":"Kodiak Sciences Inc.","url":"/issuer/0001468748","role":"Director, Ten percent owner","n_filings":22,"first_seen":"2018-10-11","last_seen":"2025-12-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001815442","name":"Kymera Therapeutics, Inc.","url":"/issuer/0001815442","role":"Director, Ten percent owner","n_filings":3,"first_seen":"2024-08-22","last_seen":"2025-12-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001157601","name":"MADRIGAL PHARMACEUTICALS, INC.","url":"/issuer/0001157601","role":"Director","n_filings":8,"first_seen":"2023-11-15","last_seen":"2025-08-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001671927","name":"Immunocore Holdings plc","url":"/issuer/0001671927","role":"Director","n_filings":1,"first_seen":"2025-03-19","last_seen":"2025-03-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001761612","name":"BICYCLE THERAPEUTICS PLC","url":"/issuer/0001761612","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2024-12-17","last_seen":"2024-12-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001496323","name":"IGM Biosciences, Inc.","url":"/issuer/0001496323","role":"Director, Ten percent owner","n_filings":3,"first_seen":"2019-09-20","last_seen":"2024-03-28"},{"type":"issuer","type_label":"ISSUER","cik":"0001404644","name":"Neoleukin Therapeutics, Inc.","url":"/issuer/0001404644","role":"Director, Ten percent owner","n_filings":4,"first_seen":"2019-08-08","last_seen":"2023-08-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001070494","name":"ACADIA PHARMACEUTICALS INC","url":"/issuer/0001070494","role":"Director, Ten percent owner","n_filings":12,"first_seen":"2013-05-17","last_seen":"2023-05-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001783328","name":"TScan Therapeutics, Inc.","url":"/issuer/0001783328","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2021-07-22","last_seen":"2022-05-12"},{"type":"issuer","type_label":"ISSUER","cik":"0000879169","name":"INCYTE CORP","url":"/issuer/0000879169","role":"Director, Ten percent owner","n_filings":10,"first_seen":"2016-02-16","last_seen":"2022-03-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001060736","name":"Seagen Inc.","url":"/issuer/0001060736","role":"Director, Ten percent owner","n_filings":38,"first_seen":"2013-12-05","last_seen":"2021-12-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001584751","name":"Talis Biomedical Corp","url":"/issuer/0001584751","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2021-02-19","last_seen":"2021-11-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001678660","name":"Prelude Therapeutics Inc","url":"/issuer/0001678660","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2020-09-30","last_seen":"2020-09-30"},{"type":"issuer","type_label":"ISSUER","cik":"0000899866","name":"ALEXION PHARMACEUTICALS, INC.","url":"/issuer/0000899866","role":"Director","n_filings":5,"first_seen":"2017-06-16","last_seen":"2020-03-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001131324","name":"GENOMIC HEALTH INC","url":"/issuer/0001131324","role":"Director, Ten percent owner","n_filings":47,"first_seen":"2012-11-14","last_seen":"2019-04-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001730430","name":"Kiniksa Pharmaceuticals, Ltd.","url":"/issuer/0001730430","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2018-05-31","last_seen":"2018-05-31"},{"type":"issuer","type_label":"ISSUER","cik":"0000861838","name":"IDERA PHARMACEUTICALS, INC.","url":"/issuer/0000861838","role":"Director","n_filings":3,"first_seen":"2015-02-17","last_seen":"2017-10-30"},{"type":"issuer","type_label":"ISSUER","cik":"0000791908","name":"XOMA Corp","url":"/issuer/0000791908","role":"Director, Ten percent owner, Other","n_filings":9,"first_seen":"2012-10-31","last_seen":"2015-07-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001576263","name":"Mirati Therapeutics, Inc.","url":"/issuer/0001576263","role":"Ten percent owner","n_filings":1,"first_seen":"2015-02-02","last_seen":"2015-02-02"},{"type":"issuer","type_label":"ISSUER","cik":"0000882796","name":"BIOCRYST PHARMACEUTICALS INC","url":"/issuer/0000882796","role":"Ten percent owner","n_filings":1,"first_seen":"2013-08-02","last_seen":"2013-08-02"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001551139","retrieved_at":"2026-08-26T21:06:44+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}